Page 21 - T Cell News Today

Researchers performed an observational study among COVID-19 patients and their close contacts registered with the Bangkok home health care services in Thailand.

Researchers investigated how age-related T-cell defects impacted the effectiveness of mRNA-based COVID-19 vaccines.

Researchers of the Hospital Universitario 12 de Octubre in Madrid and the Josep Carreras Leukaemia Research Institute have developed a cell therapy for a type of leukemia which currently has very few treatment options.

Posoleucel, an investigational allogeneic off-the-shelf T-cell therapy that simultaneously targets six different viruses, demonstrated promising antiviral efficacy and safety in a phase II study of patients who had undergone stem cell transplantation to treat their cancer or other blood diseases.

In a recent study posted to bioRxiv*, researchers designed a nanoparticle (NP)-conjugated toll-like receptor 9 (TLR9) agonist to improve the adjuvanticity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines.

Researchers analyzed T cell reactivity against alpha and beta common cold coronaviruses (CoVs) [(CCC)] to inform the development of pan-CoV vaccine concepts.

In a recent study posted to the bioRxiv* preprint server, researchers at Columbia University characterized reciprocal and non-reciprocal T-cell responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Researchers at UNC Lineberger Comprehensive Cancer Center and colleagues have found that measuring activation of immune-system B cells may be better than measuring either T-cell activation or the total number of immune cells in and around a tumor, called tumor-infiltrating lymphocytes (TILs), in predicting whether HER2-positive breast cancer responds to treatment.

Dublin, Jan. 06, 2023 (GLOBE NEWSWIRE) -- The "Global Cellular Immunotherapy Market Size, Share & Trends Analysis Report by Therapy Type (CAR T Cell...

A new study aimed to analyze whether the order of immunization of vaccine types impacted the efficacy of a heterologous prime-boost vaccination strategy.